All In Biotech

Drug Trial Radar · NCT00146627

Efficacy - Safety of Eflornithine-Nifurtimox Combination Versus Eflornithine to Treat Human African Trypanosomiasis

Clinical Study Comparing the Nifurtimox-Eflornithine Combination With the Standard Eflornithine Regimen for the Treatment of Trypanosoma Brucei Gambiense Human African Trypanosomiasis in the Meningoencephalitic Phase

Last checked: Nov 20, 2026Latest source record: Sep 29, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 280 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

280

Planned (sponsor's estimate)

Start

Not stated

Primary completion

Jun 2008

Study completion Jun 2008

Sponsor

Lead sponsor
Drugs for Neglected DiseasesAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Medecins Sans Frontieres, Netherlands; PNLTHA-DRC;; PNLTHA-RoC; Epicentre; Swiss Tropical & Public Health Institute; World Health Organization
First posted
Sep 7, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 15 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the therapeutic combination of I.V. eflornithine + oral nifurtimox to the standard IV eflornithine regimen in terms of therapeutic efficacy and clinical safety, in patients suffering from Trypanosoma brucei gambiense (Tbg) human African trypanosomiasis (HAT) in the meningoencephalitic phase.

Conditions

  • Trypanosomiasis, African

Interventions

  • EflornithineDrug

  • NifurtimoxDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

4 sites in 2 countries. Site status is shown where the registry gives one.

  • MSF-Belgium; PNLTHA, Epicentre

    Isangi, Democratic Republic of the Congo

  • PNLTHA, STI, Epicentre

    Katanda, Democratic Republic of the Congo

  • PNLTHA, STI, Epicentre

    Mbuyi Maji, Democratic Republic of the Congo

  • MSF-Holland

    Nkayi, RoC, Republic of the Congo

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.